Multisystem Inflammatory Syndrome in Children and Adolescents Associated with COVID-19: Review
Keywords:
SARS-CoV2, MIS-C, Kawasaki Disease, RT-PCR, Interleukin 6 and Interleukin 18Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C) is a newly recognized multiorgan disease seen in children, adolescent and young adults presumed to be a delayed immune mediated complication of Corona virus 2 (SARS-CoV-2) infection leading to severe acute respiratory syndrome. MIS-C can be associated with life threatening organ dysfunction requiring complex multidisciplinary care. Early recognition is important in order to prevent complication and serious sequalae. Because it is a post infective complication, in most of the cases RT-PCR comes negative though antibodies to COVID-19 are positive. Although SARS-CoV-2 in children are generally mild and nonfatal, there is increasing evidence of MIS-C. Clinical and laboratory features of MIS-C are similar to those of Kawasaki disease like syndrome and Toxic Shock Syndrome. Pathophysiology of MIS-C is still unclear and mainly due to formation of autoantibody and immune complex which activates inflammation. Most of the MIS-C associated with COVID-19, need treatment with ionotropic agents and anticoagulants. The longterm outcome of MIS-C like coronary artery aneurysm formation remain unknown and needs close follow up.
How to cite this article:
Mahapatra BS, Padhy S. Multisystem Inflammatory Syndrome in Children and Adolescents Associated with COVID-19: Review. J Adv Res Med Sci Tech 2020; 7(4): 13-15.
DOI: https://doi.org/10.24321/2394.6539.202017
References
Government of Canada. Coronavirus disease 2019 (COVID 19): epidemiology update. https://healthinfobase.canada.ca/covid 19/ epidemiological summarycovid 19 cases.html (accessed July 16, 2020).
Jones VG, Mills M, Suarez D et al. COVID 19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020; 10: 537-540.
WHO. Multisystem inflammatory syndrome in children and adolescents with COVID 19. https://www.who. int/publications/i/item/multisystem inflammatorysyndrome in children andadolescents with covid 19 (accessed July 16, 2020).
Dong Y, Mo X, Hu Y et al. Epidemiology of COVID 19 among children in China. Pediatrics 2020; 145: e20200702.
Götzinger F, Santiago García B, Noguera Julián A et al. COVID 19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020; published online June 25. https:// doi.org/10.1016/S23524642(20)30177 2.
Centers for Disease Control and Prevention. Severe outcomes among patients with coronavirus disease 2019 (COVID 19)-United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 343-346.
Ellinghaus D, Degenhardt F, Bujanda L et al. Genomewide association study of severe COVID 19 with respiratory failure. N Engl J Med 2020; published online June 17. https://doi. org/10.1056/NEJMoa2020283.
Ramcharan T, Nolan O, Lai CY et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS CoV 2 (PIMS TS): cardiac features, management and shortt erm outcomes at a UK tertiary paediatric hospital. Pediatr Cardiol 2020; published online June 12. DOI: https://doi.org/10.1007/s00246020 02391 2.
Belot A, Antona D, Renolleau S et al. SARS CoV 2 related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro Surveill 2020; 25: 2001010.
Van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631-637.
Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: is COVID 19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med 2020; 9: 1417.
Fuchs TA, Abed U, Goosmann C et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007; 176: 231-341.
Gruber C, Patel R, Trachman R et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MISC). medRxiv 2020; published online July 6. https://doi. org/10.1101/2020.07.04.20142752 (preprint).
WHO. Clinical management of Covid-19 interim guidance. 2020. https://apps.who.int/iris/handle/1 0665/332196 (accessed July 1, 2020).
Balasubramanian S, Nagendran TM, Ramachandran B, Ramanan AV. Hyper inflammatory syndrome in a child with COVID 19 treated successfully with intravenous immunoglobulin and tocilizumab. Indian Pediatr 2020; published online May 10. https://doi.org/10.1016/ S0140 6736(20)31094 1.
Verdoni L, Mazza A, Gervasoni A et al. An outbreak of severe Kawasaki like disease at the Italian epicentre of the SARS CoV 2 epidemic: an observational cohort study. Lancet 2020; 395: 1771-1778.
Greene AG, Saleh M, Roseman E, Sinert R. Toxic shock like syndrome and COVID 19: a case report of multisystem inflammatory syndrome in children (MISC). Am J Emerg Med 2020; published online June 6. https://doi.org/10.1016/j. ajem.2020.05.117.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Journal of Advanced Research in Medical Science & Technology (ISSN: 2394-6539)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
